Hikma Pharmaceuticals (LON:HIK) Stock Price Target Cut by Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK) had its price objective reduced by investment analysts at Deutsche Bank Aktiengesellschaft from GBX 2,050 to GBX 2,000 in a note issued to investors on Friday, Digital Look reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft‘s target price suggests a potential upside of 22.93% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the stock. Citigroup boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,025 target price on shares of Hikma Pharmaceuticals in a report on Thursday. Finally, Berenberg Bank raised their target price on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of GBX 2,094.17.

Hikma Pharmaceuticals Trading Down 4.1%

Shares of HIK opened at GBX 1,627 on Friday. The stock has a market capitalization of £3.37 billion, a P/E ratio of 9.24, a PEG ratio of 2.38 and a beta of 0.65. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The firm has a fifty day simple moving average of GBX 1,627.45 and a two-hundred day simple moving average of GBX 1,508.30. Hikma Pharmaceuticals has a twelve month low of GBX 1,187 and a twelve month high of GBX 1,762.

Insider Activity at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Tobias Hestler bought 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is currently owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.